



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION  
DISCLOSURE STATEMENT  
Examining Group 1614  
Patent Application  
Docket No. UF-300XC2  
Serial No. 10/666,191

February 5, 2004

  
Margaret Efron, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Laszlo Prokai, Katalin Prokai, James Simpkins  
Serial No. : 10/666,191  
Filed : September 17, 2003  
Art Unit : 1614  
Conf. No. : 8784  
For : Steroidal Quinols and Their Use for Estrogen Replacement

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§1.56, 1.97, AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that some items of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement



2

Docket No. UF-300XC2  
Serial No. 10/666,191

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.


Respectfully submitted,

Margaret Efron  
Patent Attorney  
Registration No. 47,545  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

MHE/rpj

Attachments: Form PTO/SB/08A  
Copies of references cited

**BEST AVAILABLE COPY**



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/666,191
				Filing Date	September 17, 2003
				First Named Inventor	Laszlo Prokai
				Art Unit	1614
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	UF-300XC2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US 5,108,996	04-28-1992	Claussner <i>et al.</i>	
	U2	US 5,395,831	03-07-1995	Gemmill, Jr. <i>et al.</i>	
	U3	US 5,552,395	09-03-1996	Gemmill, Jr. <i>et al.</i>	
	U4	US 5,554,601	09-10-1996	Simpkins <i>et al.</i>	
	U5	US 5,859,001	01-12-1999	Simpkins <i>et al.</i>	
	U6	US 6,197,833 B1	03-06-2001	Simpkins <i>et al.</i>	
	U7	US 6,319,914 B1	11-20-2001	Simpkins <i>et al.</i>	
	U8	US 6,583,170	06-24-2003	Pickar <i>et al.</i>	
	U9				
	U10				
	U11				
	U12				
	U13				
	U14				
	U15				
	U16				
	U17				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**BEST AVAILABLE COPY**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/666,191
Filing Date	September 17, 2003
First Named Inventor	Laszlo Prokai
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	UF-300XC2


Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	BREUER, H. and KOSTER, G. (1974) "Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level." <i>Journal of Steroid Biochemistry</i> . Vol. 5, pp. 961-967.	
	R2	GALDECKI, Z., P. et al. (1987) "Structure of 2,4-Dibromo-10 $\beta$ , 17 $\beta$ -dihydroxy-1,4-estradien-3-one" <i>Acta Cryst.</i> Vol. c43, pages 967-968.	
	R3	HIEMKE, C. et al. (1992) "Actions of Sex Hormones on the Brain." <i>Prog. Neuro-Psychopharmacol. &amp; Biol. Psychiat.</i> Vol. 16, pp. 377-388.	
	R4	KUPFER, RENE, LONG YU LIU, ALBAN J. ALLENTOFF, JOHN A. THOMPSON (2001) "Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site" <i>Biochemistry</i> 40:11490-11501.	
	R5	LIANG, Y. et al. (2001) "Membrane fluidity effects of estratrienes." <i>Brain Research Bulletin</i> . Vol. 54, No. 6, pp. 661-668.	
	R6	MCCULLOUGH, LOUISE D. and PATRICIA D. HURN (July 2003) "Estrogen and Ischemic Neuroprotection: an integrated view" <i>Trends in Endocrinology and Metabolism</i> 14(5):228-235.	
	R7	MILIC, D. et al. (1999) "X-Ray Crystal Structure of 10 $\beta$ -Hydroxy-4 $\beta$ ,5 $\beta$ -epoxyestr-1-en-3,17-dione and Antitumor Activity of its Congeners" <i>Molecules</i> , Vol. 4, pp.338-352.	
	R8	MILIC, D. et al. (1997) "The Synthesis and Biological Evaluation of A-Ring Substituted Steroidal p-Quinones" <i>Tetrahedron</i> , Vol. 53, No. 41, pp. 14073-14084.	
	R9	MILIC, D. et al. (1997) "Structure and Reactivity of Steroidal Quinones" <i>J. Serb. Chem. Soc.</i> , Vol. 62, No. 9, pp. 755-768.	
	R10	NILSEN, J. and BRINTON, D. (2003) "Divergent Impact of Progesterone and Medroxyprogesterone Acetate (Provera) on Nuclear Mitogen-activated Protein Kinase Signaling." Vol. 100, No. 18, pp.10506-10511.	
	R11	NILSEN, JON and ROBERTA DIAZ BRINTON (January 2002) "Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate" <i>Endocrinology</i> 143(1):205-212.	
	R12	NUMAZAWA, MITSUTERU, KUMIKO HOSHI, KATSUHIKO KIMURA (1989) "Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nor Steroids" <i>Chem. Pharm. Bull.</i> 37(8):2058-2062.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. his collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/666,191
Filing Date	September 17, 2003
First Named Inventor	Laszlo Prokai
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	UF-300XC2

Sheet	3	of	3
-------	---	----	---

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	OHE, TOMOYUKI, MASAOKI HIROBE, TADAHIKO MASHINO (2000) "Novel Metabolic Pathway of Estrone and 17 $\beta$ -Estradiol Catalyzed by Cytochrome P-450" <i>Drug Metabolism and Disposition</i> 28(2):110-112.	
	R2	PROKAI, K. et al. (2003) "Modifying Peptide Properties by Prodrug Design For Enhanced Transport into CNS." <i>Progress in Drug Research</i> , Vol. 61, pp. 158-188.	
	R3	PROKAI, L. et al. (2003) "Quinol-based Cyclic Antioxidant Mechanism in Estrogen Neuroprotection" <i>PNAS</i> , Vol. 100 No. 20, pp. 11741-11746.	
	R4	PROKAI, L. et al. (2003) "Short Communication: Quinol-Based Metabolic Cycle For Estrogens in Rat Liver Microsomes" <i>Drug and Metabolism and Disposition</i> , Vol. 31, No. 6, pp. 701-704.	
	R5	PROKAI, L. et al. (2001) "Synthesis and Biological Evaluation of 17 $\beta$ -Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress" <i>J. Med. Chem.</i> , Vol. 44, pp. 110-114.	
	R6	PROKAI, L., et al. (2000) "Targeting Drugs to the Brain by Redox Chemical Delivery Systems" <i>Med. Res. Rev.</i> , Vol. 20, No. 5, pp. 367-416.	
	R7	SOLAJA, B. et al. (1996) "A Novel <i>m</i> -CPBA Oxidation: <i>p</i> -Quinols and Epoxyquinols from Phenols" <i>Tetrahedron Letters</i> . Vol. 37, No. 21, pp. 3765-3768.	
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. his collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.